25 results on '"Nobutake Tanaka"'
Search Results
2. An outcome analysis of predictive factors for portal or splenic vein thrombosis after distal pancreatectomy
- Author
-
Hideki Takami, Tsutomu Fujii, Masahiko Koike, Nobutake Tanaka, Yasuhiro Kodera, Fuminori Sonohara, Suguru Yamada, Goro Nakayama, Masamichi Hayashi, and Michitaka Fujiwara
- Subjects
Male ,Laparoscopic surgery ,medicine.medical_specialty ,Abdominal Abscess ,Left gastric vein ,medicine.medical_treatment ,Gastroenterology ,Benign tumor ,03 medical and health sciences ,Mesenteric Veins ,Pancreatectomy ,Postoperative Complications ,Surgical Staplers ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Vein ,Abscess ,Retrospective Studies ,Venous Thrombosis ,Portal Vein ,business.industry ,Age Factors ,General Medicine ,medicine.disease ,Dissection ,Treatment Outcome ,medicine.anatomical_structure ,Splenic Vein ,Splenic vein ,030220 oncology & carcinogenesis ,Inferior mesenteric vein ,Female ,Laparoscopy ,030211 gastroenterology & hepatology ,Surgery ,business ,Organ Sparing Treatments ,Forecasting - Abstract
The aim of this study was to explore predictive factors for portal or splenic vein thrombosis (VT) that might cause serious problems after distal pancreatectomy (DP). A total of 230 patients who underwent DP between 2008 and 2017 were retrospectively reviewed to identify predictive factors for portal or splenic VT. Ultimately, 164 patients were analyzed. Portal or splenic VT was significantly correlated with age
- Published
- 2020
3. A Case of Splenic Vein Reconstruction Combined with Portal Vein Resection in Pancreatoduodenectomy
- Author
-
Shigeaki Sawada, Tsutomu Fujii, Katsuhisa Hirano, Takuya Nagata, Yuuko Tohmatsu, Kazuto Shibuya, Tomoyuki Okumura, Toru Watanabe, Isaku Yoshioka, and Nobutake Tanaka
- Subjects
medicine.medical_specialty ,business.industry ,Splenic vein ,Portal vein ,General Earth and Planetary Sciences ,Medicine ,Radiology ,business ,General Environmental Science ,Resection - Published
- 2020
4. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy
- Author
-
Hiroshi Tanabe, Fuminori Sonohara, Yuki Sunagawa, Nobutake Tanaka, Chie Tanaka, Mitsuro Kanda, Yasuhiro Kodera, Masamichi Hayashi, Hideki Takami, Yoshikuni Inokawa, Keisuke Kurimoto, Masahiko Koike, Suguru Yamada, and Goro Nakayama
- Subjects
Adult ,Male ,medicine.medical_specialty ,Surgical margin ,medicine.medical_treatment ,Gastroenterology ,Methylation ,Pancreaticoduodenectomy ,Genomic Imprinting ,Tumor budding ,Predictive Value of Tests ,Internal medicine ,Pancreatic cancer ,Genetics ,medicine ,Humans ,Molecular Biology ,Genetics (clinical) ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Stomach ,Research ,Hazard ratio ,Margins of Excision ,DNA Methylation ,Middle Aged ,medicine.disease ,Pancreatic Neoplasms ,medicine.anatomical_structure ,Cancer cell ,Carcinoma, Squamous Cell ,Field cancerization ,Female ,Neoplasm Recurrence, Local ,business ,Developmental Biology - Abstract
Background Pancreatic cancer is one of the lethal cancers among solid malignancies. Pathological diagnosis of surgical margins is sometimes unreliable due to tissue shrinkage, invisible field cancerization and skipped lesions like tumor budding. As a result, tumor recurrences sometimes occur even from the pathologically negative surgical margins. Methods We applied molecular surgical margin (MSM) analysis by tissue imprinting procedure to improve the detection sensitivity of tiny cancerous cells on the surgical specimen surface after pancreatoduodenectomy. Surgical specimens were collected from 45 pancreatic cancer cases who received subtotal stomach preserving pancreatoduodenectomy at Nagoya University Hospital during 2017–2019. Quantitative methylation-specific PCR (QMSP) of the original methylation marker panel (CD1D, KCNK12, PAX5) were performed and analyzed with postoperative survival outcomes. Results Among 45 tumors, 26 cases (58%) were QMSP-positive for CD1D, 25 (56%) for KCNK12 and 27 (60%) for PAX5. Among the 38 tumors in which at least one of the three markers was positive, CD1D-positive cancer cells, KCNK12-positive cancer cells, and PAX5-positive cancer cells were detected at the surgical margin in 8 cases, 7 cases and 10 cases, respectively. Consequently, a total of 17 patients had at least one marker detected at the surgical margin by QMSP, and these patients were defined as MSM-positive. They were associated with significantly poor recurrence-free survival (p = 0.002) and overall survival (p = 0.005) than MSM-negative patients. Multivariable analysis showed that MSM-positive was the only significant independent factor for worse recurrence-free survival (hazard ratio: 3.522, 95% confidence interval: 1.352–9.179, p = 0.010). On the other hand, a significant proportion of MSM-negative cases were found to have received neoadjuvant chemotherapy (p = 0.019). Conclusion Pancreatic cancer-specific methylation marker panel was established to perform MSM analysis. MSM-positive status might represent microscopically undetectable cancer cells on the surgical margin and might influence the postoperative long-term outcomes.
- Published
- 2021
5. A Case of Accidental Ingestion of a Partial Denture, Treated by Thoracotomic Esophageal Foreign Body Removal
- Author
-
Nobutake Tanaka, Kenji Taniguchi, Yoshinari Mochizuki, Hiroyuki Sugimoto, Tomohisa Otsu, and Hiroyuki Yokoyama
- Subjects
medicine.medical_specialty ,business.industry ,Accidental ingestion ,Esophageal foreign body ,Medicine ,business ,Surgery - Published
- 2019
6. Different Characteristics of Serum Alfa Fetoprotein and Serum Des-gamma-carboxy Prothrombin in Resected Hepatocellular Carcinoma
- Author
-
Fuminori Sonohara, Hideki Takami, Suguru Yamada, Goro Nakayama, Yoshikuni Inokawa, Yasuhiro Kodera, Norifumi Hattori, Nao Takano, Masahiko Koike, Masamichi Hayashi, Dai Shimizu, Mitsuro Kanda, Nobutake Tanaka, Chie Tanaka, and Yukiyasu Okamura
- Subjects
Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatitis C virus ,medicine.disease_cause ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Japan ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,Protein Precursors ,neoplasms ,Tumor marker ,Pharmacology ,Hepatitis B virus ,business.industry ,Des gamma carboxy prothrombin ,Hazard ratio ,Liver Neoplasms ,HCCS ,medicine.disease ,digestive system diseases ,Hepatocellular carcinoma ,Prothrombin ,alpha-Fetoproteins ,business ,Survival predictors ,Biomarkers ,Research Article - Abstract
Background/Aim: Hepatocellular carcinoma (HCC) mainly develops in the damaged liver from hepatitis C virus (HCV) or hepatitis B virus (HBV) infection in Japan. On the other hand, the occurrence of HCCs derived from the liver without viral infection has recently been increasing. Our aim was to identify characteristics specific to HCCs with virus-infected liver (HCC-BC) or those with non-B- and non-C-infected liver (HCC-NBNC), Patients and Methods: We collected preoperative serum α-fetoprotein (AFP) and Des-Gamma-Carboxy Prothrombin (DCP), also known as PIVKA-II values from surgically resected HCC cases during 1994-2017 in our department. Results: Preoperative serum AFP values of HCC-BC cases (n=284) were higher compared to HCC-NBNC cases (n=88) (p=0.016), whereas serum DCP values of HCC-NBNC cases were higher compared to HCC-BC cases (p
- Published
- 2021
7. Extended pleurectomy decortication for Masaoka stage IVa thymoma with massive pleural and pericardial dissemination
- Author
-
Yusuke Muranishi, Tomoya Kono, Seiki Hasegawa, Hideaki Miyamato, Nobutake Tanaka, and Ryo Miyahara
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Thymoma ,medicine.medical_treatment ,Diaphragmatic breathing ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,medicine.artery ,Medicine ,Humans ,business.industry ,Mediastinum ,General Medicine ,Thymus Neoplasms ,Decortication ,Middle Aged ,medicine.disease ,Surgery ,Dissection ,medicine.anatomical_structure ,Thoracotomy ,030220 oncology & carcinogenesis ,Descending aorta ,Pleura ,Masaoka Stage IVa ,Cardiology and Cardiovascular Medicine ,business ,Pleurectomy ,Pericardium - Abstract
We herein report two cases of Masaoka stage IVa thymoma treated by radical resection via thymothymectomy followed by pleurectomy/decortication (PD). Case 1: a 52-year-old man was diagnosed with a type B1 thymoma. Resection of the right lobe of thymus, dissection of left upper mediastinum, and pleurectomy from anterior chest wall to descending aorta were performed via median sternotomy approach. Pericardial resection followed by decortication of the total visceral pleura was then successfully performed via a posterolateral thoracotomy approach. Case 2: a 48-year-old man was diagnosed with type B2 thymoma. Thymothymectomy and extra-pleural dissection except for the right-side diaphragmatic area were achieved via median sternotomy approach. Resection of the visible disseminated lesions of visceral pleura was performed after pleurectomy of the diaphragmatic area via posterolateral thoracotomy approach. Both patients are disease free at 3 years and 2 years and half, respectively. Extended thymothymectomy followed by PD is a candidate approach for surgical management.
- Published
- 2020
8. A case of peripheral lung torsion
- Author
-
Hidehiro Shimizu, Tomoya Kono, Nobutake Tanaka, and Ryo Miyahara
- Subjects
Lung ,medicine.anatomical_structure ,business.industry ,Torsion (mechanics) ,Medicine ,Anatomy ,business ,Peripheral - Published
- 2018
9. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer
- Author
-
Yasuhiro Kodera, Tsutomu Fujii, Norifumi Hattori, Hideki Takami, Fuminori Sonohara, Masahiko Koike, Suguru Yamada, Goro Nakayama, Mitsuro Kanda, Nobutake Tanaka, Daisuke Kobayashi, Masamichi Hayashi, Naoki Iwata, Chie Tanaka, Masaya Suenaga, Yukiko Niwa, and Michitaka Fujiwara
- Subjects
Male ,0301 basic medicine ,lcsh:Medicine ,Apoptosis ,Vimentin ,medicine.disease_cause ,Metastasis ,Cohort Studies ,0302 clinical medicine ,Cell Movement ,Tumor Cells, Cultured ,lcsh:Science ,Aged, 80 and over ,Regulation of gene expression ,Multidisciplinary ,biology ,LOXL2 ,Middle Aged ,Prognosis ,Gene Expression Regulation, Neoplastic ,Survival Rate ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Amino Acid Oxidoreductases ,Adult ,Epithelial-Mesenchymal Transition ,Lysyl oxidase ,Article ,Gene Expression Regulation, Enzymologic ,03 medical and health sciences ,Pancreatic cancer ,Biomarkers, Tumor ,medicine ,Humans ,Neoplasm Invasiveness ,Epithelial–mesenchymal transition ,Aged ,Cell Proliferation ,business.industry ,lcsh:R ,medicine.disease ,Pancreatic Neoplasms ,030104 developmental biology ,biology.protein ,Cancer research ,lcsh:Q ,business ,Carcinogenesis ,Follow-Up Studies - Abstract
Lysyl oxidase (LOX) family genes, particularly lysyl oxidase-like protein 2 (LOXL2), have been implicated in carcinogenesis, metastasis, and the epithelial-to-mesenchymal transition (EMT) in various cancers. This study aimed to explore the clinical implications of LOXL2 expression in pancreatic cancer (PC) in the context of EMT status. LOX family mRNA expression was measured in PC cell lines, and LOXL2 protein levels were examined in surgical specimens resected from 170 patients with PC. Higher LOXL2 expression was observed in cell lines from mesenchymal type PC than in those from epithelial type PC. A significant correlation between LOXL2 expression and the EMT status defined based on the expression of E-cadherin and vimentin was observed in surgical specimens (P P P = 0.03) was a significant independent prognostic factor for patients with PC. Additionally, LOX inhibition significantly decreased PC cell proliferation, migration, and invasion in vitro. In conclusion, LOXL2 expression is potentially associated with PC progression, and LOXL2 expression represents a biomarker for predicting the prognosis of patients with PC who have undergone complete resection.
- Published
- 2018
10. Tumor-Forming Autoimmune Pancreatitis Confused with Pancreatic Cancer That Developed during the Course of Chronic Pancreatitis
- Author
-
Yasuhiro Kodera, Hiroyuki Sugimoto, Hideki Takami, Mitsuru Tashiro, Tsutomu Fujii, Nobutake Tanaka, Masamichi Hayashi, Suguru Yamada, and Daishi Morimoto
- Subjects
medicine.medical_specialty ,business.industry ,General surgery ,Gastroenterology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Pancreatic cancer ,Internal medicine ,medicine ,Pancreatitis ,030211 gastroenterology & hepatology ,Surgery ,business ,Autoimmune pancreatitis - Published
- 2017
11. Usefulness of Intraoperative Angiography in a Hybrid Operating Room for Pancreaticoduodenectomy in Patients with Celiac Axis Stenosis: Report of Two Cases
- Author
-
Hiroyuki Sugimoto, Hideki Takami, Kojiro Suzuki, Mitsuru Tashiro, Daishi Morimoto, Nobutake Tanaka, Yasuhiro Kodera, Suguru Yamada, Masamichi Hayashi, and Tsutomu Fujii
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Intraoperative angiography ,Gastroenterology ,Celiac axis ,Pancreaticoduodenectomy ,medicine.disease ,03 medical and health sciences ,Stenosis ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Hybrid operating room ,030211 gastroenterology & hepatology ,Surgery ,In patient ,Radiology ,business - Published
- 2017
12. A case of primary pleuropulmonary synovial sarcoma treated by multidisciplinary treatment strategy including extrapleural pneumonectomy
- Author
-
Yasumiko Tone, Ryo Miyahara, Syunsuke Iimori, Nobutake Tanaka, Takuya Terashi, and Hidehiro Shimizu
- Subjects
0301 basic medicine ,Extrapleural Pneumonectomy ,medicine.medical_specialty ,business.industry ,medicine.disease ,Synovial sarcoma ,Surgery ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Treatment strategy ,business - Published
- 2017
13. Splenic Aneurysm Near the Origin of Splenic Artery and Splenic Hamartoma with Stricture of the Celiac Artery Due to Median Arcuate Ligament Compression
- Author
-
Suguru Yamada, Mitsuru Tashiro, Tsutomu Fujii, Daishi Morimoto, Nobutake Tanaka, Kojiro Suzuki, Hiroyuki Sugimoto, Masamichi Hayashi, Hideki Takami, and Yasuhiro Kodera
- Subjects
medicine.medical_specialty ,business.industry ,Median arcuate ligament ,Gastroenterology ,030204 cardiovascular system & hematology ,Splenic artery ,medicine.disease ,Compression (physics) ,03 medical and health sciences ,0302 clinical medicine ,Aneurysm ,medicine.anatomical_structure ,Celiac artery ,030220 oncology & carcinogenesis ,medicine.artery ,Medicine ,Surgery ,Radiology ,business ,Splenic hamartoma - Published
- 2017
14. Comparison of non-invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma
- Author
-
Haruyoshi Tanaka, Michitaka Fujiwara, Nobutake Tanaka, Hideki Takami, Daisuke Kobayashi, Masahiko Koike, Fuminori Sonohara, Daishi Morimoto, Suguru Yamada, Goro Nakayama, Masamichi Hayashi, Yasuhiro Kodera, Mitsuru Tashiro, Yuki Sunagawa, Chie Tanaka, and Mitsuro Kanda
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Non invasive ,Area under the curve ,Fibrosis stage ,Perioperative ,medicine.disease ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Fibrosis ,030220 oncology & carcinogenesis ,Internal medicine ,Hepatocellular carcinoma ,medicine ,030211 gastroenterology & hepatology ,Hepatectomy ,business ,Survival analysis - Abstract
Aim This study aimed to assess the clinical utility of preoperative evaluation of liver fibrosis using platelet-albumin-bilirubin (PALBI) grade, Fibrosis-4 index (FIB-4), and aspartate transaminase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients and explore the clinical impact of these models with regard to perioperative risks and HCC prognosis. Methods Between January 2003 and December 2018, 305 consecutive patients who underwent hepatectomy for HCC were enrolled. Results The APRI showed the most robust diagnostic performance through each fibrosis stage among three models (PALBI, FIB-4, and APRI): fibrosis stage 3 (f3), area under the curve [AUC] = 0.55, 0.72, and 0.76; and f4, AUC = 0.51, 0.71, and 0.76, respectively). In addition, survival analysis revealed that all three models were significantly associated with HCC prognosis. PALBI (grade 1 vs. 2, 3): recurrence-free survival (RFS): median survival time (MST), 34 vs. 17 months, 0.007; overall survival (OS): MST, 115 vs. 68, 0.02. FIB-4 (grade 1, 2 vs. 3): RFS: MST, 34 vs. 22, 0.004, OS: MST, 120 vs. 63, 0.0001. APRI (grade 1, 2 vs. 3), RFS: MST, 30 vs. 20, 0.0005; OS: MST, 107 vs. 55, 0.0003. Among three scoring systems, only PALBI grade was significantly associated with both operative time (median, 303 vs. 340 min, 0.01) and intraoperative blood loss (median, 581 vs. 859 mL, 0.03). Conclusions This study showed robust performances of selected liver reserve and fibrosis models to predict HCC prognosis. Of them, PALBI might be used for assessing perioperative risks for hepatectomy for HCC.
- Published
- 2019
15. Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial)
- Author
-
Daishi Morimoto, Y. Ito, Satoshi Morita, H. Nakayama, M. Sakai, Kei Tanaka, Sadanori Ito, K. Uemura, Yoshinari Mochizuki, Nobutake Tanaka, Kazunari Misawa, Yasuhiro Kodera, T. Matsui, and Hitoshi Teramoto
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Adenocarcinoma ,Gastroenterology ,Disease-Free Survival ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Gastrectomy ,Recurrence ,Stomach Neoplasms ,Internal medicine ,Clinical endpoint ,Medicine ,Humans ,Peritoneal Lavage ,Survival rate ,Peritoneal Neoplasms ,Aged ,Intraoperative Care ,business.industry ,Surrogate endpoint ,Standard treatment ,Hazard ratio ,Cancer ,Middle Aged ,medicine.disease ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Surgery ,Female ,business - Abstract
A survival benefit of extensive intraoperative peritoneal lavage (EIPL) has been reported in patients with gastric cancer with positive peritoneal cytology. The hypothesis of this study was that EIPL may reduce peritoneal recurrence in patients with advanced gastric cancer who undergo surgery with curative intent.This was an open-label, multi-institutional, randomized, phase 3 trial to assess the effects of EIPL versus standard treatment after curative gastrectomy for resectable gastric cancer of T3 status or above. The primary endpoint was disease-free survival (DFS); secondary endpoints were overall survival, peritoneal recurrence-free survival and incidence of adverse events.Between July 2011 and January 2014, 314 patients were enrolled from 15 institutions and 295 patients were analysed (145 and 150 in the EIPL and no-EIPL groups respectively). The 3-year DFS rate was 63·9 (95 per cent c.i. 55·5 to 71·2) per cent in the EIPL group and 59·7 (51·3 to 67·1) per cent in the control group (hazard ratio (HR) 0·81, 95 per cent c.i. 0·57 to 1·16; P = 0·249). The 3-year overall survival rate was 75·0 (67·1 to 81·3) per cent in the EIPL group and 73·7 (65·9 to 80·1) per cent in the control group (HR 0·91, 0·60 to 1·37; P = 0·634). Peritoneal recurrence-free survival was not significantly different between the two groups (HR 0·92, 0·62 to 1·36; P = 0·676). No intraoperative complications related to EIPL were observed.EIPL did not improve survival or peritoneal recurrence in patients who underwent gastrectomy for advanced gastric cancer. Registration number: 000005907 (http://www.umin.ac.jp/ctr/index.htm).Se ha descrito que un lavado peritoneal extenso intraoperatorio (extensive intraoperative peritoneal lavage, EIPL) proporciona un beneficio en la supervivencia en pacientes con cáncer gástrico con citología peritoneal positiva. La hipótesis de este estudio era que el EIPL podría disminuir la recidiva peritoneal en pacientes con cáncer gástrico avanzado sometidos a cirugía con intención curativa. MÉTODOS: Ensayo clínico fase 3, abierto, multicéntrico y aleatorizado para evaluar los efectos de un lavado peritoneal extenso intraoperatorio (EIPL) frente a tratamiento estándar tras gastrectomía curativa por cáncer gástrico ≥T3 resecable. La variable de resultado primaria fue la supervivencia libre de enfermedad (disease-free survival, DFS), y las variables de resultado secundarias fueron la supervivencia global (overall survival, OS), la supervivencia libre de recidiva peritoneal y la incidencia de efectos adversos.Entre julio de 2011 y enero de 2014, se reclutaron 314 pacientes de 15 instituciones y se analizaron los datos de 295 pacientes (145 en el grupo con EIPL y 150 en el grupo sin EIPL). La DFS a los 3 años fue 63,9% (i.c. del 95% 55,5-71,2) en el grupo con EIPL y 59,7% (i.c. del 95% 51,3-67,1) en el grupo control (cociente de riesgos instantáneos, hazard ratio, HR 0,81 (i.c. del 95% 0,57-1,16), P = 0,249). La OS a los 3 años fue 75,0% (i.c. del 95% 67,1-81,3) en el grupo con EIPL y 73,7% (i.c. del 95% 65,9-80,1) en el grupo control (HR 0,91 i.c. del 95% 0,60-1,37), P = 0,634). No se observaron diferencias estadísticamente significativas entre los dos grupos en la supervivencia libre de recidiva peritoneal (P = 0,676, HR 0,92 (i.c. del 95% 0,62-1,36). No se observaron complicaciones intraoperatorias relacionadas con EIPL. CONCLUSIÓN: El EIPL no mejoró la supervivencia o la recidiva peritoneal en pacientes sometidos a gastrectomía por cáncer gástrico avanzado.
- Published
- 2019
16. Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma
- Author
-
Masaya Suenaga, Yasuhiro Kodera, Hiroyuki Sugimoto, Yukiko Niwa, Norifumi Hattori, Masamichi Hayashi, Mitsuro Kanda, Suguru Yamada, Nobutake Tanaka, Masahiko Koike, Goro Nakayama, Daisuke Kobayashi, Fuminori Sonohara, Michitaka Fujiwara, Chie Tanaka, and Hideki Takami
- Subjects
medicine.medical_specialty ,Bilirubin ,ALBI‐TNM score ,medicine.medical_treatment ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,hepatectomy ,Internal medicine ,Medicine ,Stage (cooking) ,Survival analysis ,albumin‐bilirubin grade ,business.industry ,Proportional hazards model ,Perioperative ,Original Articles ,hepatocellular carcinoma ,medicine.disease ,chemistry ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Surgery ,Original Article ,Hepatectomy ,business ,Indocyanine green - Abstract
Background and Aim A reliable classification for predicting postoperative prognosis and perioperative risk of hepatocellular carcinoma (HCC) patients is required to make a precise decision for HCC treatment. In the present study, we assessed the perioperative and prognostic importance of indocyanine green (ICG) testing, tumor‐node‐metastasis (TNM) stage, albumin‐bilirubin (ALBI) grade, and ALBI‐TNM (ALBI‐T) score using consecutive resected HCC cases. Methods Between 1998 and 2011, 273 consecutive patients who underwent primary and curative hepatectomy for HCC were identified. Among these 273 cases, 235 Child‐Pugh class A patients were enrolled in the present study. Results Correlation analysis showed that the value of linear predictor for ALBI grade was significantly correlated with ICG 15‐minute retention rates (r = 0.51, P
- Published
- 2018
17. Intravenous scheduled administration of acetaminophen in analgesia after pancreatectomy
- Author
-
Tsutomu Fujii, Ayaka Itoh, Kei Sugano, Kazuto Shibuya, Toru Watanabe, Nana Kimura, Tomoyuki Okumura, Isaku Yoshioka, Nobutake Tanaka, and Katsuhisa Hirano
- Subjects
Hepatology ,business.industry ,Anesthesia ,medicine.medical_treatment ,Pancreatectomy ,Gastroenterology ,Medicine ,business ,Administration (government) ,Acetaminophen ,medicine.drug - Published
- 2019
18. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment
- Author
-
Hideki Takami, Nobutake Tanaka, Tsutomu Fujii, Kenta Murotani, Yasuhiro Kodera, Isaku Yoshioka, Suguru Yamada, Kazuto Shibuya, and Tomoyuki Okumura
- Subjects
Inverse probability of treatment weighting ,medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Medicine ,Adenocarcinoma ,business ,medicine.disease ,Abutment (dentistry) ,Surgery ,Neoadjuvant chemoradiotherapy - Published
- 2018
19. Analysis of predictive factors for portal and splenic vein thrombosis after distal pancreatectomy
- Author
-
Tsutomu Fujii, Hideki Takami, Masamichi Hayashi, Nobutake Tanaka, Daishi Morimoto, Suguru Yamada, Hiroyuki Sugimoto, and Yasuhiro Kodera
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Endocrinology, Diabetes and Metabolism ,General surgery ,Gastroenterology ,medicine ,Splenic vein thrombosis ,Distal pancreatectomy ,business ,Surgery - Published
- 2017
20. A Case of Mediastinitis due to Perforation of the Cervical Esophagus Associated with Dermatomyositis
- Author
-
Naomi Hayashi, Koichi Kato, Nobutake Tanaka, Kiyoshi Ishigure, Hirohumi Kuroda, Atushi Hirai, Naoko Ishida, Go Ninomiya, Junichi Tobinaga, and Yoichi Ito
- Subjects
medicine.medical_specialty ,business.industry ,Perforation (oil well) ,Gastroenterology ,medicine ,Surgery ,Radiology ,Cervical esophagus ,Dermatomyositis ,business ,medicine.disease ,Mediastinitis - Published
- 2011
21. Clinical implication of inflammation-based prognostic score and perioperative nutrition control in pancreatic cancer
- Author
-
Daishi Morimoto, Hideki Takami, Go Ninomiya, Nobutake Tanaka, Chie Tanaka, Mitsuro Kanda, Masamichi Hayashi, Mitsuru Tashiro, Hiroyuki Sugimoto, Naoki Iwata, Tsutomu Fujii, Nao Takano, Yukiko Niwa, Daisuke Kobayashi, Yasuhiro Kodera, Michitaka Fujiwara, Suguru Yamada, Goro Nakayama, and Masahiko Koike
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Lymphocyte ,Cancer ,Inflammation ,Perioperative ,Systemic inflammation ,medicine.disease ,Gastroenterology ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Parenteral nutrition ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Pancreatic cancer ,medicine ,030212 general & internal medicine ,medicine.symptom ,Neutrophil to lymphocyte ratio ,business - Abstract
390 Background: Systemic inflammation and nutrition status are considered to influence survival in cancer patients. A variety of systemic inflammation-based prognostic scores have been explored; however, there has been no study to clarify which score could best reflect survival in resected pancreatic cancer patients. Methods: Between 2002 and 2016, 422 consecutive patients who underwent curative resection of pancreatic cancer were enrolled. The Glasgow Prognostic Score (GPS), modified GPS (mGPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), prognostic index (PI), and prognostic nutritional index (PNI) scores for each patients were calculated. Survival of each score was evaluated, and correlations between the score selected on the basis of the prognostic significance and various clinicopathological factors were analyzed. On the other hand, the nutrition markers (pre-albumin, transferrin, and retinol-binding protein) of 30 patients who received the enteral nutrition during the perioperative period were also evaluated. Results: In the analysis of the GPS, the median survival time (MST) was 29.4 months for score 0, 25.5 for score 1, and 17.7 for score 2 ( p< 0.001), and mGPS was also found to be significant ( p= 0.003). On the contrary, there were no significance in MST between other scores (NLR, PLR, PI, or PNI). Multivariate analysis revealed that lymph node metastasis, positive peritoneal washing cytology, and a GPS score of 2 were significant prognostic factors. There was also statistically significant correlation between the GPS score and tumor location (head), tumor size ( > 2.0cm), bile duct invasion, and duodenal invasion. In terms of nutrition status, the postoperative nutrition markers of 30 patients managed by enteral nutrition tended to recover earlier than 79 patients managed by intravenous nutrition. Conclusions: Our results demonstrated that the GPS could be an independent predictive marker and was superior to other inflammation-based prognostic scores in patients with resected pancreatic cancer. The results also suggested that perioperative nutrition support and infection control would improve survival of pancreatic cancer patients.
- Published
- 2017
22. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106)
- Author
-
Junichi Sakamoto, Keisuke Kurimoto, Akimasa Nakao, Nobutake Tanaka, Akiharu Ishiyama, Kiyoshi Ishigure, Yoshinari Mochizuki, Takanori Matsui, Seiji Ito, Hiroshi Nakayama, Daisuke Kobayashi, and Yasuhiro Kodera
- Subjects
inorganic chemicals ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Adenocarcinoma ,Young Adult ,Japan ,Surgical oncology ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Stage (cooking) ,Young adult ,Aged ,Neoplasm Staging ,Tegafur ,Cisplatin ,Postoperative Care ,Chemotherapy ,business.industry ,Gastroenterology ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Regimen ,Drug Combinations ,Oxonic Acid ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Feasibility Studies ,Female ,business ,Adjuvant ,medicine.drug ,Follow-Up Studies - Abstract
The standard of care for stage II/III gastric cancer in Japan is D2 dissection followed by adjuvant S-1 monotherapy. Outcome of patients with stage III disease remains unsatisfactory, calling for a more intensive adjuvant chemotherapy regimen, for which evidence in advanced/metastatic cancer research suggests S-1/cisplatin (CDDP) as a candidate. Although S-1/CDDP was poorly tolerated postoperatively in the previous trial, compliance was dramatically improved by insertion of one cycle of S-1 monotherapy, which delayed administration of CDDP by 6 weeks.A feasibility study of post-gastrectomy S-1/CDDP was performed. Patients with stage III/IV gastric cancer were eligible. The first cycle of chemotherapy consisted of S-1 monotherapy, and intensive antiemetic drugs were prescribed when patients were administered CDDP. The primary endpoint was the completion rate of four cycles of S-1/CDDP. The secondary endpoints were the relative dose intensity, safety, progression-free survival time and overall survival time. Several criteria to skip, postpone or reduce the dose had been predetermined.Between 2010 and 2011, 33 patients were enrolled. Four patients had stage IIIA disease, 7 patients had stage IIIB disease, 11 patients had stage IIIC disease, and 11 patients had stage IV disease. The completion rate of the protocol treatment was 60.6%. The relative dose intensity of S-1 was 77.3% and that of CDDP was 72.3%.The protocol-specified delay in the administration of CDDP dramatically improved the relative drug intensity in the postoperative adjuvant setting, although the completion rate did not reach the expected level.
- Published
- 2013
23. MON-PP272: Multi-Institutional Prospective Study to Explore the Efficacy of Oral Nutritional Supplements in the Early Postoperative Period for Gastric Cancer Patients
- Author
-
T. Okada, S. Ito, M. Yamanaka, H. Hasegawa, Nobutake Tanaka, Y. Morioka, Y. Uno, Kiyoshi Ishigure, Yoshinari Mochizuki, Yasuhiro Kodera, Kazunari Misawa, H. Kojima, H. Nakayama, D. Kobayashi, and T. Matsumura
- Subjects
medicine.medical_specialty ,Nutrition and Dietetics ,business.industry ,Internal medicine ,Period (gene) ,medicine ,Cancer ,Critical Care and Intensive Care Medicine ,Prospective cohort study ,medicine.disease ,business ,Surgery - Published
- 2015
24. Multi-institutional prospective study to explore the efficacy of oral nutritional supplements for the patients undergoing gastrectomy against gastric cancer (CCOG1301)
- Author
-
Yasuyuki Asai, Kiyoshi Ishigure, Yoshinari Mochizuki, Michitaka Fujiwara, Daisuke Kobayashi, Seiji Ito, Nobutake Tanaka, Tatsuki Matsumura, Kazunari Misawa, Tomomi Okada, Hiroshi Nakayama, Hiroshi Kojima, Akira Fujioka, Chie Tanaka, Yoshiyasu Kato, Yasuaki Uno, Yuki Morioka, Masaya Yamanaka, Yasuhiro Kodera, and Hirotaka Hasegawa
- Subjects
Cancer Research ,medicine.medical_specialty ,Adjuvant chemotherapy ,business.industry ,General surgery ,medicine.medical_treatment ,Cancer ,medicine.disease ,Surgery ,Malnutrition ,Oncology ,medicine ,Gastrectomy ,Lymphadenectomy ,Prospective cohort study ,business - Abstract
e15039 Background: Gastrectomy with lymphadenectomy and adjuvant chemotherapy is one of standards for treatment of gastric cancer (GC). Postoperative malnutrition is deemed inevitable, however, and...
- Published
- 2015
25. Clinical benefits of bevacizumab in metastatic colorectal cancer depending on KRAS status
- Author
-
Yoshiyasu Kato, Keisuke Kurimoto, Hiruhumi Kuroda, Hidenobu Matsushita, Nobutake Tanaka, Song Ryo, Kiyoshi Ishigure, Yasuyuki Asai, Tomoo Fujii, Junichi Tobinaga, and Ryuichi Fukuyama
- Subjects
Oncology ,Drug ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,business.industry ,media_common.quotation_subject ,medicine.disease_cause ,medicine.disease ,digestive system diseases ,Internal medicine ,medicine ,KRAS ,business ,neoplasms ,medicine.drug ,media_common - Abstract
636 Background: KRAS status is the therapeutic marker of anti-EGFR drug, and may be the prognostic marker of metastatic colorectal cancer (mCRC). However, there is no consensus whether bevacizumab (anti-VEGF drug) benefits patients with mutated KRAS in mCRC. We investigated the clinical benefits of bevacizumab treatment in mCRC depending on KRAS status, retrospectively. Methods: We investigated 49 patients who received chemotherapies with bevacizumab as first-line treatment for mCRC from May 2008 through June 2013. We evaluated response rate (RR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), tumor reduction rate and the adverse events (CTCAE v4.0 - JCOG) depending on KRAS status. Results: The median age of the patients was 66 years (range; 36 - 80). Forty-five patients received oxaliplatin-based chemotherapies with bevacizumab and four patients received irinotecan-based chemotherapies with bevacizumab. KRAS status of 30 patients was wild type and that of 19 patients was mutation type. There was no difference in patient characteristics between KRAS wild type (WT) and mutation type (MT). In all 49 patients, RR was 62.5%. DCR was 91.7%. The median PFS was 10.9 months. In RR, patients with KRAS wild type tumors had better outcome than patients with mutant type tumors (WT : MT, 69.0% : 52.6%, no statistically difference). A similar tendency was seen in DCR (WT : MT, 96.6% : 84.2%, no statistically difference). The average reduction rate in KRAS WT was 42.7% and in KRAS MT was 32.3% (p = 0.309). In the KRAS wild patients, the median PFS was longer than that in the KRAS mutant patients (WT : MT, 11.8 : 8.9 months, Log Rank p = 0.583), but there is no statistically difference between two groups. In median OS, there was no difference between two groups (WT : MT, 21.0 : 20.8 months, Log Rank p = 0.393). The incidence of severe adverse events was not statistically different between KRAS WT group and MT group. Conclusions: Regardless of KRAS status, bevacizumab provides clinical benefits for patients with mCRC.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.